Multimodal imaging assessment of nigrostriatal pathway in Parkinson’s disease using 11C-PE2I PET and neuromelanin-sensitive MR
Objective: To evaluate the nigrostratal pathway with multimodal assessment using striatal 11C-PE2I PET and nigral Neuromelanin-sensitive MR in Parkinson's disease. Background: The main pathological features…Striatal PDE10 expression in Parkinson’s disease (PD) and healthy controls using [18F]MNI-659 PET imaging
Objective: To evaluate the feasibility of [18F]MNI-659 PET, a striatal PDE10A imaging tracer, as a imaging biomarker in PD. Background: PDE10 is highly and specifically…Comparison of DAT and DOPA PET tracer for assessing severity and progression in patients with Parkinson’s disease
Objective: The aims of this study were to quantify striatal uptake of 18F-DOPA and 11C-PE2I in the same group of PD patients, to assess the…
- « Previous Page
- 1
- …
- 31
- 32
- 33